Advertisement

Peripartum Cardiomyopathy

  • Abdallah Georges Kfoury
  • Kismet D. Rasmusson
  • Kimberly D. Brunisholz
  • T. Flint Porter
  • Benjamin D. Horne
Chapter

Abstract

Peripartum cardiomyopathy (PPCM) is an uncommon but important form of left ventricular systolic dysfunction with global implications. Its pathophysiology is likely multifactorial and may include a genetic predisposition. Our understanding of PPCM has been challenged by the lack of prospective studies and large registries. The clinical presentation, diagnostic assessment, and treatment usually mirror those of other forms of dilated cardiomyopathy. However, pregnancy status and breastfeeding are important considerations. While acknowledging that a fair number of patients with PPCM will have recovery of cardiac function, advanced heart failure therapies should be considered in a timely manner to improve short- and long-term outcomes. Subsequent pregnancies are associated with increased risk for the mother and fetus and generally should be discouraged, even in the setting of normalized ventricular function. Further advances in the knowledge of PPCM will stem from an emerging prospective study and through creating large-scale national/international registries.

Keywords

Peripartum cardiomyopathy Heart failure Pregnancy 

References

  1. 1.
    Richie C. Clinical contributions to the pathology, diagnosis, and treatment of certain chronic disease of the heart. Edinb Med Surg J. 1849;2(333).Google Scholar
  2. 2.
    Hull E, Hafkesbring E. “Toxic” postpartal heart disease. New Orleans Med Surg J. 1937;89:550.Google Scholar
  3. 3.
    Demakis JG, Rahimtoola SH. Peripartum cardiomyopathy. Circulation. 1971;44(5):964–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Pearson GD, et al. Peripartum cardiomyopathy: national heart, lung, and blood institute and office of rare diseases (National Institutes of Health) workshop recommendations and review. JAMA. 2000;283(9):1183–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Sliwa K, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail. 2010;12(8):767–78.PubMedCrossRefGoogle Scholar
  6. 6.
    Mielniczuk LM, et al. Frequency of peripartum cardiomyopathy. Am J Cardiol. 2006;97(12):1765–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Pyatt JR, Dubey G. Peripartum cardiomyopathy: current understanding, comprehensive management review and new developments. Postgrad Med J. 2011;87(1023):34–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Goland S, et al. Clinical profile and predictors of complications in peripartum cardiomyopathy. J Card Fail. 2009;15(8):645–50.PubMedCrossRefGoogle Scholar
  9. 9.
    Elkayam U, et al. Pregnancy-associated cardiomyopathy: clinical characteristics and a comparison between early and late presentation. Circulation. 2005;111(16):2050–5.PubMedCrossRefGoogle Scholar
  10. 10.
    Sliwa K, et al. Outcome of subsequent pregnancy in patients with documented peripartum cardiomyopathy. Am J Cardiol. 2004;93(11):1441–3, A10.PubMedCrossRefGoogle Scholar
  11. 11.
    Sliwa K, Tibazarwa K, Hilfiker-Kleiner D. Management of peripartum cardiomyopathy. Curr Heart Fail Rep. 2008;5(4):238–44.PubMedCrossRefGoogle Scholar
  12. 12.
    Gunderson EP, et al. Epidemiology of peripartum cardiomyopathy: incidence, predictors, and outcomes. Obstet Gynecol. 2011;118(3):583–91.PubMedCrossRefGoogle Scholar
  13. 13.
    Sliwa K, Fett J, Elkayam U. Peripartum cardiomyopathy. Lancet. 2006;368(9536):687–93.PubMedCrossRefGoogle Scholar
  14. 14.
    Corbacho AM, Martinez De La Escalera G, Clapp C. Roles of prolactin and related members of the prolactin/growth hormone/placental lactogen family in angiogenesis. J Endocrinol. 2002;173(2):219–38.PubMedCrossRefGoogle Scholar
  15. 15.
    Hilfiker-Kleiner D, et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell. 2007;128(3):589–600.PubMedCrossRefGoogle Scholar
  16. 16.
    Hilfiker-Kleiner D, Sliwa K, Drexler H. Peripartum cardiomyopathy: recent insights in its pathophysiology. Trends Cardiovasc Med. 2008;18(5):173–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Hilfiker-Kleiner D, et al. Recovery from postpartum cardiomyopathy in 2 patients by blocking prolactin release with bromocriptine. J Am Coll Cardiol. 2007;50(24):2354–5.PubMedCrossRefGoogle Scholar
  18. 18.
    Sliwa K, et al. Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients. Eur Heart J. 2006;27(4):441–6.PubMedCrossRefGoogle Scholar
  19. 19.
    Forster O, et al. Reversal of IFN-gamma, oxLDL and prolactin serum levels correlate with clinical improvement in patients with peripartum cardiomyopathy. Eur J Heart Fail. 2008;10(9):861–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Sliwa K, et al. The addition of pentoxifylline to conventional therapy improves outcome in patients with peripartum cardiomyopathy. Eur J Heart Fail. 2002;4(3):305–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Fett JD. Viral infection as a possible trigger for the development of peripartum cardiomyopathy. Int J Gynaecol Obstet. 2007;97(2):149–50.PubMedCrossRefGoogle Scholar
  22. 22.
    Sanderson JE, Olsen EG, Gatei D. Peripartum heart disease: an endomyocardial biopsy study. Br Heart J. 1986;56(3):285–91.PubMedCrossRefGoogle Scholar
  23. 23.
    Midei MG, et al. Peripartum myocarditis and cardiomyopathy. Circulation. 1990;81(3):922–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Felker GM, et al. Myocarditis and long-term survival in peripartum cardiomyopathy. Am Heart J. 2000;140(5):785–91.PubMedCrossRefGoogle Scholar
  25. 25.
    Bultmann BD, et al. High prevalence of viral genomes and inflammation in peripartum cardiomyopathy. Am J Obstet Gynecol. 2005;193(2):363–5.PubMedCrossRefGoogle Scholar
  26. 26.
    Ansari AA, et al. Autoimmune mechanisms as the basis for human peripartum cardiomyopathy. Clin Rev Allergy Immunol. 2002;23(3):301–24.PubMedCrossRefGoogle Scholar
  27. 27.
    Lamparter S, Pankuweit S, Maisch B. Clinical and immunologic characteristics in peripartum cardiomyopathy. Int J Cardiol. 2007;118(1):14–20.PubMedCrossRefGoogle Scholar
  28. 28.
    Warraich RS, et al. Impact of pregnancy-related heart failure on humoral immunity: clinical relevance of G3-subclass immunoglobulins in peripartum cardiomyopathy. Am Heart J. 2005;150(2):263–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Maron BJ, et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. 2006;113(14):1807–16.PubMedCrossRefGoogle Scholar
  30. 30.
    Elliott P, et al. Classification of the cardiomyopathies. Kardiol Pol. 2008;66(5):533–40; discussion 541–2.PubMedGoogle Scholar
  31. 31.
    Massad LS, et al. Familial peripartum cardiomyopathy after molar pregnancy. Obstet Gynecol. 1993;81(5 (Pt 2)):886–8.PubMedGoogle Scholar
  32. 32.
    Pierce JA, Price BO, Joyce JW. Familial occurrence of postpartal heart failure. Arch Intern Med. 1963;111:651–5.PubMedCrossRefGoogle Scholar
  33. 33.
    Pearl W. Familial occurrence of peripartum cardiomyopathy. Am Heart J. 1995;129(2):421–2.PubMedCrossRefGoogle Scholar
  34. 34.
    Fett JD, et al. Mother-daughter peripartum cardiomyopathy. Int J Cardiol. 2002;86(2–3):331–2.PubMedCrossRefGoogle Scholar
  35. 35.
    Cowan J, et al. Genetic testing and genetic counseling in cardiovascular genetic medicine: overview and preliminary recommendations. Congest Heart Fail. 2008;14(2):97–105.PubMedCrossRefGoogle Scholar
  36. 36.
    van Spaendonck-Zwarts KY, et al. Peripartum cardiomyopathy as a part of familial dilated cardiomyopathy. Circulation. 2010;121(20):2169–75.PubMedCrossRefGoogle Scholar
  37. 37.
    Morales A, et al. Rare variant mutations in pregnancy-associated or peripartum cardiomyopathy. Circulation. 2010;121(20):2176–82.PubMedCrossRefGoogle Scholar
  38. 38.
    Horne BD, et al. Genome-wide significance and replication of the chromosome 12p11.22 locus near the PTHLH gene for peripartum cardiomyopathy. Circ Cardiovasc Genet. 2011;4(4):359–66.PubMedCrossRefGoogle Scholar
  39. 39.
    Fett JD. Validation of a self-test for early diagnosis of heart failure in peripartum cardiomyopathy. Crit Pathw Cardiol. 2011;10(1):44–5.PubMedCrossRefGoogle Scholar
  40. 40.
    Ray P, Murphy GJ, Shutt LE. Recognition and management of maternal cardiac disease in pregnancy. Br J Anaesth. 2004;93(3):428–39.PubMedCrossRefGoogle Scholar
  41. 41.
    Abboud J, et al. Peripartum cardiomyopathy: a comprehensive review. Int J Cardiol. 2007;118(3):295–303.PubMedCrossRefGoogle Scholar
  42. 42.
    Renz DM, et al. New insights into peripartum cardiomyopathy using cardiac magnetic resonance imaging. Rofo. 2011;183(9):834–41.PubMedCrossRefGoogle Scholar
  43. 43.
    Mouquet F, et al. Characterisation of peripartum cardiomyopathy by cardiac magnetic resonance imaging. Eur Radiol. 2008;18(12):2765–9.PubMedCrossRefGoogle Scholar
  44. 44.
    Hunt SA, et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119(14):e391–479.PubMedCrossRefGoogle Scholar
  45. 45.
    Cooper LT, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Circulation. 2007;116(19):2216–33.PubMedCrossRefGoogle Scholar
  46. 46.
    Hu CL, et al. Troponin T measurement can predict persistent left ventricular dysfunction in peripartum cardiomyopathy. Heart. 2007;93(4):488–90.PubMedCrossRefGoogle Scholar
  47. 47.
    Velickovic IA, Leicht CH. Peripartum cardiomyopathy and cesarean section: report of two cases and literature review. Arch Gynecol Obstet. 2004;270(4):307–10.PubMedCrossRefGoogle Scholar
  48. 48.
    Elkayam U. Clinical characteristics of peripartum cardiomyopathy in the United States: diagnosis, prognosis, and management. J Am Coll Cardiol. 2011;58(7):659–70.PubMedCrossRefGoogle Scholar
  49. 49.
    Goland S, et al. Evaluation of the clinical relevance of baseline left ventricular ejection fraction as a predictor of recovery or persistence of severe dysfunction in women in the United States with peripartum cardiomyopathy. J Card Fail. 2011;17(5):426–30.PubMedCrossRefGoogle Scholar
  50. 50.
    Safirstein JG, et al. Predictors of left ventricular recovery in a cohort of peripartum cardiomyopathy patients recruited via the internet. Int J Cardiol. 2012;154(1):27–31.PubMedCrossRefGoogle Scholar
  51. 51.
    Amos AM, Jaber WA, Russell SD. Improved outcomes in peripartum cardiomyopathy with contemporary. Am Heart J. 2006;152(3):509–13.PubMedCrossRefGoogle Scholar
  52. 52.
    Francis GS, et al. ACCF/AHA/ACP/HFSA/ISHLT 2010 clinical competence statement on management of patients with advanced heart failure and cardiac transplant: a report of the ACCF/AHA/ACP Task Force on Clinical Competence and Training. J Am Coll Cardiol. 2010;56(5):424–53.PubMedCrossRefGoogle Scholar
  53. 53.
    Gynaecologists R.C.o.O.a. Reducing the risk of thromboembolism during pregnancy, birth, and the puerperium. Guideline no. 37. 2009;London: RCOG.Google Scholar
  54. 54.
    James AH, et al. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol. 2006;194(5):1311–5.PubMedCrossRefGoogle Scholar
  55. 55.
    Holzgreve W, Carey JC, Hall BD. Warfarin-induced fetal abnormalities. Lancet. 1976;2(7991):914–5.PubMedCrossRefGoogle Scholar
  56. 56.
    Bozkurt B, et al. Intravenous immune globulin in the therapy of peripartum cardiomyopathy. J Am Coll Cardiol. 1999;34(1):177–80.PubMedCrossRefGoogle Scholar
  57. 57.
    Fett JD. Personal commentary: monitoring subsequent pregnancy in recovered peripartum cardiomyopathy mothers. Crit Pathw Cardiol. 2009;8(4):172–4.PubMedCrossRefGoogle Scholar
  58. 58.
    Elkayam U, et al. Maternal and fetal outcomes of subsequent pregnancies in women with peripartum cardiomyopathy. N Engl J Med. 2001;344(21):1567–71.PubMedCrossRefGoogle Scholar
  59. 59.
    Karaye KM, Henein MY. Peripartum cardiomyopathy: a review article. Int J Cardiol. 2013;164(1):33–8.PubMedCrossRefGoogle Scholar
  60. 60.
    Fett JD, Christie LG, Murphy JG. Brief communication: outcomes of subsequent pregnancy after peripartum cardiomyopathy: a case series from Haiti. Ann Intern Med. 2006;145(1):30–4.PubMedCrossRefGoogle Scholar
  61. 61.
    Reimold SC, Rutherford JD. Peripartum cardiomyopathy. N Engl J Med. 2001;344(21):1629–30.PubMedCrossRefGoogle Scholar
  62. 62.
    Elkayam U, Goland S. Bromocriptine for the treatment of peripartum cardiomyopathy. Circulation. 2010;121(13):1463–4.PubMedCrossRefGoogle Scholar
  63. 63.
    Ecker JL, Frigoletto Jr FD. Cesarean delivery and the risk-benefit calculus. N Engl J Med. 2007;356(9):885–8.PubMedCrossRefGoogle Scholar
  64. 64.
    Cooper LT, et al. Myocardial recovery in peripartum cardiomyopathy: prospective comparison with recent onset cardiomyopathy in men and nonperipartum women. J Card Fail. 2012;18(1):28–33.PubMedCrossRefGoogle Scholar
  65. 65.
    Rasmusson K, et al. Long term outcomes in patients with peripartum cardiomyopathy and no recovery of left ventricular function. J Card Fail. 2010;16:S97.CrossRefGoogle Scholar
  66. 66.
    Witlin AG, Mabie WC, Sibai BM. Peripartum cardiomyopathy: an ominous diagnosis. Am J Obstet Gynecol. 1997;176(1 Pt 1):182–8.PubMedCrossRefGoogle Scholar
  67. 67.
    Rasmusson K, et al. Peripartum cardiomyopathy: post-transplant outcomes from the united network for organ sharing database. J Heart Lung Transplant. 2012;31(2):180–6.PubMedCrossRefGoogle Scholar
  68. 68.
    Rasmusson K, et al. Predictors of graft survival in heart transplant recipients with peripartum cardiomyopathy: insights from the United Network for Organ Sharing (UNOS) database. J Heart Lung Transplant. 2012;31(4S):S137.CrossRefGoogle Scholar
  69. 69.
    Fett JD, et al. Five-year prospective study of the incidence and prognosis of peripartum cardiomyopathy at a single institution. Mayo Clin Proc. 2005;80(12):1602–6.PubMedCrossRefGoogle Scholar
  70. 70.
    Brar SS, et al. Incidence, mortality, and racial differences in peripartum cardiomyopathy. Am J Cardiol. 2007;100(2):302–4.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2014

Authors and Affiliations

  • Abdallah Georges Kfoury
    • 1
  • Kismet D. Rasmusson
    • 2
  • Kimberly D. Brunisholz
    • 3
  • T. Flint Porter
    • 4
  • Benjamin D. Horne
    • 5
  1. 1.Department of CardiologyIntermountain Medical CenterSalt Lake CityUSA
  2. 2.Heart Failure Program Development Lead, Intermountain Medical CenterUniversity of Utah College of Nursing, The Heart Institute, Heart Failure and Transplant ProgramSalt Lake CityUSA
  3. 3.Department of Cardiovascular ResearchIntermountain Medical Center, Intermountain Heart InstituteSalt Lake CityUSA
  4. 4.Division of Maternal-Fetal Medicine, Department of Obstetrics and GynecologyIntermountain Medical Center, University of UtahSalt Lake CityUSA
  5. 5.Division of Genetic EpidemiologyIntermountain Medical Center and University of Utah, Intermountain Heart InstituteSalt Lake CityUSA

Personalised recommendations